The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations to treat adults with relapsed or refractory ...

GSK plc announced the approval of Blenrep combinations by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma. The approval ...

The number of newborns in Japan is decreasing faster than projected, with the number of annual births falling to another record low last year, according to government data released Wednesday.

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma. The London-based ...

Policymakers are worried about Japan's future as the population plummets.

GSK said combinations of its blood-cancer treatment, Blenrep, have been approved by Japan's Ministry of Health, and that it expects more approvals through the year.

Japan's population has been shrinking for 15 years, with huge implications for the country's economy, national defense, and culture. Now, policymakers are working to boost birth rates.

This trial evaluated Blenrep in combination with inhibitors and anti-inflammatory treatments. The trial involved patients with multiple myeloma who had received at least one prior therapy. GSK ...

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...